NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $41.5455.

Several equities research analysts have recently issued reports on NAMS shares. Citigroup started coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They set a “buy” rating and a $42.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a “buy” rating and a $44.00 price objective on the stock. Royal Bank Of Canada boosted their price target on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Wells Fargo & Company assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, August 25th. They issued an “overweight” rating and a $45.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $24.05 on Tuesday. The stock has a market cap of $2.71 billion, a P/E ratio of -14.85 and a beta of -0.01. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The firm’s 50 day moving average price is $22.41 and its 200-day moving average price is $20.41.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.37. The firm had revenue of $19.15 million for the quarter, compared to analysts’ expectations of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. As a group, equities analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 8,269 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $24.86, for a total value of $205,567.34. Following the sale, the chief accounting officer owned 15,000 shares in the company, valued at approximately $372,900. The trade was a 35.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Douglas F. Kling sold 51,043 shares of the business’s stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $21.10, for a total transaction of $1,077,007.30. Following the completion of the sale, the chief operating officer owned 44,000 shares in the company, valued at $928,400. This represents a 53.71% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 12,835 shares of company stock worth $248,134 and have sold 256,881 shares worth $5,445,954. Insiders own 20.84% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its stake in NewAmsterdam Pharma by 2.4% during the second quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock worth $408,000 after buying an additional 521 shares during the period. The Manufacturers Life Insurance Company boosted its stake in NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after buying an additional 544 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock worth $80,000 after buying an additional 596 shares during the period. Quarry LP purchased a new position in NewAmsterdam Pharma during the first quarter worth $25,000. Finally, BNP Paribas Financial Markets boosted its stake in NewAmsterdam Pharma by 4.5% during the second quarter. BNP Paribas Financial Markets now owns 29,277 shares of the company’s stock worth $530,000 after buying an additional 1,257 shares during the period. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.